Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 77Lymphoma 62Melanoma 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Large B-Cell, Diffuse 42Leukemia 41Lymphoma, Non-Hodgkin 31Burkitt Lymphoma 30Multiple Myeloma 28Leukemia, Lymphocytic, Chronic, B-Cell 26Neuroblastoma 24Lymphoma, Follicular 23Neoplasm Metastasis 21Leukemia, Myeloid, Acute 19Sarcoma 18Lymphoma, Large-Cell, Immunoblastic 18Neoplasms, Plasma Cell 17Lymphoma, Mantle-Cell 17Skin Neoplasms 16Ovarian Neoplasms 14Kidney Neoplasms 14Neoplasms 13Hodgkin Disease 13Myelodysplastic Syndromes 12Lymphoma, B-Cell, Marginal Zone 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, B-Cell 11Central Nervous System Neoplasms 11Pancreatic Neoplasms 10Lymphoma, Large-Cell, Anaplastic 10

Interventions

obeticholic acid 1fludarabine 1aldesleukin 1Specimen Handling 1Endoscopy, Gastrointestinal 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Duodenal Neoplasms × Cyclophosphamide × Clear all
NCT06690281 2025-09-11

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Duodenal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡